EP1578996A4 - COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS - Google Patents
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORSInfo
- Publication number
- EP1578996A4 EP1578996A4 EP03813488A EP03813488A EP1578996A4 EP 1578996 A4 EP1578996 A4 EP 1578996A4 EP 03813488 A EP03813488 A EP 03813488A EP 03813488 A EP03813488 A EP 03813488A EP 1578996 A4 EP1578996 A4 EP 1578996A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- diagnosing
- compositions
- methods
- treating tumors
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41898802P | 2002-10-18 | 2002-10-18 | |
| US418988P | 2002-10-18 | ||
| PCT/US2003/029126 WO2004060270A2 (en) | 2002-10-18 | 2003-10-15 | Compositions and methods for the diagnosis and treatment of tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1578996A2 EP1578996A2 (en) | 2005-09-28 |
| EP1578996A4 true EP1578996A4 (en) | 2007-12-19 |
Family
ID=32712943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03813488A Withdrawn EP1578996A4 (en) | 2002-10-18 | 2003-10-15 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1578996A4 (en) |
| JP (1) | JP2006516192A (en) |
| AU (1) | AU2003303144A1 (en) |
| CA (1) | CA2503043A1 (en) |
| WO (1) | WO2004060270A2 (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030157082A1 (en) * | 2002-01-31 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules |
| AU2003226131A1 (en) * | 2002-03-28 | 2003-10-13 | Bristol-Myers Squibb Company | Novel human cell surface protein with immunoglobulin folds, bgs-19 |
| WO2003091402A2 (en) * | 2002-04-23 | 2003-11-06 | University Of Georgia Research Foundation, Inc. | N-ACETYLGLUCOSAMINYLTRANSFERASE Vb CODING SEQUENCE, RECOMBINANT CELLS AND METHODS |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| JP2005230011A (en) * | 2004-02-20 | 2005-09-02 | Samsung Electronics Co Ltd | Breast cancer-related protein, gene encoding the same, and protein and diagnostic method for breast cancer using the gene |
| NZ553162A (en) | 2004-08-16 | 2010-03-26 | Quark Biotech Inc | Double stranded siRNA compounds that inhibit RRTP801 |
| GB0422211D0 (en) * | 2004-10-06 | 2004-11-03 | Randox Lab Ltd | Method |
| WO2006044566A2 (en) * | 2004-10-13 | 2006-04-27 | A & G Pharmaceutical, Inc. | Autocrine growth factor receptors and methods |
| JP2007008844A (en) * | 2005-06-29 | 2007-01-18 | Nippon Flour Mills Co Ltd | Monoclonal antibody specifically reacting with septin 2 protein, hybridoma producing the same, cancer detection method and cancer detection kit |
| UY30097A1 (en) | 2006-01-20 | 2007-08-31 | Atugen Ag | THERAPEUTIC USES OF RTP801 INHIBITORS |
| US20070237713A1 (en) | 2006-04-04 | 2007-10-11 | Fan Rong A | PCan065 Antibody Compositions and Methods of Use |
| WO2008054534A2 (en) | 2006-05-11 | 2008-05-08 | Quark Pharmaceuticals, Inc. | Screening systems utilizing rtp801 |
| US8700335B2 (en) * | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
| WO2007141796A2 (en) | 2006-06-09 | 2007-12-13 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of rtp801l |
| WO2008106102A2 (en) | 2007-02-26 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
| WO2008148072A2 (en) * | 2007-05-24 | 2008-12-04 | The Brigham And Women's Hospital, Inc. | Disease-associated genetic variations and methods for obtaining and using same |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| US20110251090A1 (en) * | 2008-08-27 | 2011-10-13 | Oncotherapy Science, Inc. | Pancreatic cancer related gene ttll4 |
| MX2011008430A (en) | 2009-02-20 | 2011-09-29 | Ganymed Pharmaceuticals Ag | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER. |
| EP3689911B1 (en) | 2009-11-11 | 2024-08-21 | Astellas Pharma Inc. | Antibodies specific for claudin 6 (cldn6) |
| WO2011150400A1 (en) * | 2010-05-28 | 2011-12-01 | New York Blood Center, Inc. | Nuclear scaffold protein stip/tfip11 target for cancer therapy |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| EP3026064B1 (en) | 2011-05-13 | 2018-10-17 | Ganymed Pharmaceuticals GmbH | Antibodies for treatment of cancer expressing claudin 6 |
| DK2928921T3 (en) | 2012-12-05 | 2021-04-19 | Novartis Ag | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES TARGETED EPO |
| ES2967701T3 (en) * | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Synergistic enhancement of nucleic acid delivery via blended formulations |
| WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| ES2913530T3 (en) | 2015-08-12 | 2022-06-02 | Novartis Ag | Methods for treating ophthalmic disorders |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| KR20200018488A (en) | 2017-05-24 | 2020-02-19 | 토리스 게엠베하 | Use of glutamine synthase to treat hyperammonemia |
| US12274733B2 (en) | 2018-09-28 | 2025-04-15 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| WO2020069373A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| WO2020069339A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Mutant reverse tetracycline transactivators for expression of genes |
| JP7766904B2 (en) * | 2021-06-04 | 2025-11-11 | 地方独立行政法人東京都健康長寿医療センター | Pharmaceutical composition for treating prostate cancer |
| US12252518B2 (en) | 2023-01-06 | 2025-03-18 | Life Biosciences, Inc. | Methods of treating non-arteritic anterior ischemic optic neuropathy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002016581A2 (en) * | 2000-08-24 | 2002-02-28 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1445318A2 (en) * | 2000-08-24 | 2004-08-11 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| JP2004520810A (en) * | 2000-08-24 | 2004-07-15 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
-
2003
- 2003-10-15 AU AU2003303144A patent/AU2003303144A1/en not_active Abandoned
- 2003-10-15 CA CA002503043A patent/CA2503043A1/en not_active Abandoned
- 2003-10-15 WO PCT/US2003/029126 patent/WO2004060270A2/en not_active Ceased
- 2003-10-15 EP EP03813488A patent/EP1578996A4/en not_active Withdrawn
- 2003-10-15 JP JP2004564724A patent/JP2006516192A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| DATABASE EMBL/GENBANK/DDBJ 13 June 2001 (2001-06-13), STRAUSBERG, R.L. ET AL: "Homo sapiens papillary renal cell carcinoma", XP002446467, retrieved from EBI Database accession no. BC010450 * |
| WETERMAN MARIAN A J ET AL: "Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1) (p11;q21)-positive papillary renal cell carcinomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 26, 1996, pages 15294 - 15298, XP002446464, ISSN: 0027-8424 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003303144A1 (en) | 2004-07-29 |
| CA2503043A1 (en) | 2004-07-22 |
| EP1578996A2 (en) | 2005-09-28 |
| WO2004060270A2 (en) | 2004-07-22 |
| WO2004060270A8 (en) | 2005-07-14 |
| JP2006516192A (en) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1571968A4 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR | |
| EP1578371A4 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS | |
| EP1572091A4 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS | |
| EP1663259A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| EP1696877A4 (en) | METHODS FOR TREATING PAIN | |
| EP1796666A4 (en) | METHODS AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA | |
| EP1585482A4 (en) | NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS | |
| EP1639090A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER | |
| EP1961065A4 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER | |
| EP1583504A4 (en) | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER | |
| EP1578940A4 (en) | METHODS AND COMPOSITIONS FOR DIAGNOSING DYSPLASIA | |
| EP1814909A4 (en) | USE OF AIMP2DX2 FOR DIAGNOSING AND TREATING CANCER | |
| IL176259A0 (en) | Compositions and methods for treating diabetes | |
| EP1575580A4 (en) | METHODS OF TREATING CANCERS | |
| EP1660009A4 (en) | METHODS OF TREATING ENDOMETRIOSIS | |
| EP1576110A4 (en) | COMPOSITIONS INHIBITING CELL MIGRATION AND METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP1677735A4 (en) | METHODS AND COMPOSITIONS FOR MODULATING THE FUNCTION OF ADIPOCYTES | |
| NO20054711D0 (en) | Methods and pharmaceutical compositions for the palpable uptake of acceptable serum testosterone levels | |
| EP1575571A4 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR | |
| NO20040058L (en) | Content reading apparatus | |
| EP1648474A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR SCALING LESIONS | |
| EP1442062A4 (en) | CARCINOMA TREATMENT METHODS | |
| FR2851452B1 (en) | MINI-BLADE ANATOMIC PLATE ALLOWING OSTEOSYNTHESIS OF THE FIRST PHALANGE | |
| EP1774043A4 (en) | COMPOSITIONS, KITS AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING AND TREATING CANCER | |
| EP1626711A4 (en) | COMPOSITIONS AND METHODS FOR ANTICANCER TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050425 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ZHOU, YAN Inventor name: WU, THOMAS, D. |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GENENTECH, INC. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20071119 |
|
| 17Q | First examination report despatched |
Effective date: 20080728 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20090210 |